Article
Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.
Psychopharmacology - 1 Jun 2017
Peterson Kimberly, Dieperink Eric, Anderson Johanna, Boundy Erin, Ferguson Lauren, Helfand Mark
Abstract excerpt
OBJECTIVE: This study aims to conduct an evidence review of the effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment for major depressive disorder. METHODS: We searched MEDLINE®, the Cochrane Central Registry of Controlled Trials, and PsycINFO through February 2017. We used prespecified criteria to select studies, abstract data, and rate internal validity and strength...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.